Biologic compounds have revolutionized disease treatment with high specificity and efficacy. Traditionally, these biologics are administered as subcutaneous injections or infusions, but patient aversion to injections often leads to delayed use. As a compelling alternative, the nose offers a route to systemic circulation due to its large surface area and thin epithelial layer, facilitating rapid and effective drug absorption, as demonstrated by intranasal glucagon.
Learn more about using Iconovo’s ICOone Nasal to deliver biologics through the nose with an easy sniff. Here you can watch the presentation by CTO Orest Lastow at the meeting New updates in Drug Formulation & Bioavailability, organized by Life Science Sweden in Copenhagen on August 28.
ICOone Nasal
Single-dose dry powder inhaler now for nasal use, ideal for short-term treatments that only require a few doses for full effect.
Bill & Melinda Gates Foundation supports ICOone Nasal
Iconovo has received a grant from the Bill & Melinda Gates Foundation, to develop a nasal inhaler helping people across the globe to gain access to crucial medicines.